v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Product revenue $ 226 $ 45
Operating expenses:    
Cost of sales 206 33
Research and development 563 601
Sales and marketing 18 10
General and administrative [1] 1,045 1,071
Total operating expenses 1,832 1,715
Operating loss (1,606) (1,670)
Other income (expense), net:    
Interest income 2 13
Interest expense (2) (2)
Other income 5 0
Other income (expense), net 5 11
Net loss $ (1,601) $ (1,659)
Basic and diluted net loss per share (in dollars per share) $ (0.09) $ (0.1)
Weighted average common shares outstanding, basic and diluted (in shares) 17,580,744 15,918,979
Comprehensive loss:    
Net loss $ (1,601) $ (1,659)
Foreign currency translation adjustments 4 0
Comprehensive loss $ (1,597) $ (1,659)
[1] Certain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the three months ended March 31, 2026 and 2025, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead.